ABSTRACT
Epithelial tumor cells often acquire malignant properties, such as invasion/metastasis and uncontrolled cell growth, by undergoing epithelial-mesenchymal transition (EMT). However, the mechanisms by which EMT contributes to malignant progression remain elusive. Here we show that the Rho guanine nucleotide exchange factor (GEF) ARHGEF5 promotes tumor malignancy in a manner dependent on EMT status. We previously identified ARHGEF5, a member of the Dbl family of GEFs, as a multifunctional mediator of Src-induced cell invasion and tumor growth. In the present study, ARHGEF5 was upregulated during tumor growth factor-ß-induced EMT in human epithelial MCF10A cells, and promoted cell migration by activating the Rho-ROCK pathway. ARHGEF5 was necessary for the invasive and in vivo metastatic activity of human colorectal cancer HCT116 cells. These findings underscore the crucial role of ARHGEF5 in cell migration and invasion/metastasis. An in vivo tumorigenesis assay revealed that ARHGEF5 had the potential to promote tumor growth via the phosphatidylinositol 3-kinase (PI3K) pathway. However, ARHGEF5 was not required for tumor growth in epithelial-like human colorectal cancer HCT116 and HT29 cells, whereas the growth of mesenchymal-like SW480 and SW620 cells depended on ARHGEF5. Induction of EMT by tumor necrosis factor-α or Slug in HCT116 cells resulted in the dependence of tumor growth on ARHGEF5. In these mesenchymal-like cells, Akt was activated via ARHGEF5 and its activity was required for tumor growth. Analysis of a transcriptome data set revealed that the combination of ARHGEF5 upregulation and E-cadherin downregulation or Snail upregulation was significantly correlated with poor prognosis in patients with colorectal cancers. Taken together, our findings suggest that EMT-induced ARHGEF5 activation contributes to the progression of tumor malignancy. ARHGEF5 may serve as a potential therapeutic target in a subset of malignant tumors that have undergone EMT.
ABSTRACT
c-Src is upregulated in various human cancers, suggesting its role in malignant progression. However, the molecular circuits of c-Src oncogenic signaling remain elusive. Here we show that Fer tyrosine kinase oligomer mediates and amplifies Src-induced tumor progression. Previously, we showed that transformation of fibroblasts is promoted by the relocation of c-Src to non-raft membranes. In this study, we identified Fer and ezrin as non-raft c-Src targets. c-Src directly activated Fer by initiating its autophosphorylation, which was further amplified by Fer oligomerization. Fer interacted with active c-Src at focal adhesion membranes and activated Fer-phosphorylated ezrin to induce cell transformation. Fer was also crucial for cell transformation induced by v-Src or epidermal growth-factor receptor activation. Furthermore, Fer activation was required for tumorigenesis and invasiveness in some cancer cells in which c-Src is upregulated. We propose that the Src-Fer axis represents a new therapeutic target for treatment of a subset of human cancers.
Subject(s)
Colonic Neoplasms/metabolism , Colonic Neoplasms/pathology , Protein-Tyrosine Kinases/metabolism , src-Family Kinases/metabolism , Animals , CSK Tyrosine-Protein Kinase , Cell Line, Tumor , Cell Transformation, Neoplastic/metabolism , Cytoskeletal Proteins/metabolism , ErbB Receptors/metabolism , Focal Adhesions/metabolism , Gene Expression Regulation, Neoplastic , Humans , Mice, Inbred BALB C , Phosphorylation , Protein-Tyrosine Kinases/genetics , Signal Transduction , Xenograft Model Antitumor Assays , src-Family Kinases/geneticsABSTRACT
The tyrosine kinase c-Src is upregulated in various human cancers; however, the molecular mechanisms underlying c-Src-mediated tumor progression remain unclear. Here we show that downregulation of microRNA (miR)-542-3p is tightly associated with tumor progression via c-Src-related oncogenic pathways. In c-Src-transformed fibroblasts and human cancer cells that overexpress c-Src, miR-542-3p is substantially downregulated, and the ectopic expression of miR-542-3p suppresses tumor growth. We identified the integrin-linked kinase (ILK) as a conserved target of miR-542-3p. ILK upregulation promotes cell adhesion and invasion by activating the integrin-focal adhesion kinase (FAK)/c-Src pathway, and can also contribute to tumor growth via the AKT and glycogen synthase kinase 3ß pathways. MiR-542-3p expression is downregulated by the activation of c-Src-related signaling molecules, including epidermal growth factor receptor, K-Ras and Ras/Raf/mitogen-activated protein kinase/extracellular signal-regulated kinase. In human colon cancer tissues, downregulation of miR-542-3p is significantly correlated with the upregulation of c-Src and ILK. Our results suggest that the novel c-Src-miR-542-3p-ILK-FAK circuit plays a crucial role in controlling tumor progression.
Subject(s)
MicroRNAs/metabolism , Neoplasms/genetics , Protein Serine-Threonine Kinases/metabolism , Protein-Tyrosine Kinases/metabolism , Animals , CSK Tyrosine-Protein Kinase , Cell Adhesion/drug effects , Cell Line , Colonic Neoplasms/genetics , Disease Progression , Focal Adhesion Kinase 1/metabolism , Humans , Mice , Neoplasm Invasiveness/genetics , Neoplasms/metabolism , Up-Regulation , src-Family KinasesABSTRACT
The tyrosine kinase c-Src is upregulated in various human cancers, but the molecular mechanisms underlying c-Src-mediated tumor growth remain unclear. Here we examined the involvement of microRNAs in the c-Src-mediated tumor growth. Microarray profiling revealed that c-Src activation downregulates a limited set of microRNAs, including miR-99a, which targets oncogenic mammalian target of rapamycin (mTOR) and fibroblast growth factor receptor 3 (FGFR3). Re-expression of miR-99a suppressed tumor growth of c-Src-transformed cells, and this effect was restored by the overexpression of mTOR. The downregulation of miR-99a was also observed in epidermal growth factor- and Ras-transformed cells, and it was suppressed by inhibiting the mitogen-activated protein kinase (MAPK) pathway. Furthermore, miR-99a downregulation is associated with mTOR/FGFR3 upregulation in various human lung cancer cells/tissues. The tumorigenicity of these cells was suppressed by the introduction of miR-99a. These findings suggest that the miR-99a-mTOR/FGFR3 pathway is crucial for controlling tumor growth in a wide range of human cancers that harbor upregulation of the Src-related oncogenic pathways.
Subject(s)
MicroRNAs/genetics , Neoplasms/genetics , Receptor, Fibroblast Growth Factor, Type 3/genetics , TOR Serine-Threonine Kinases/genetics , src-Family Kinases/genetics , Animals , Cell Line , Cell Proliferation/drug effects , Cell Transformation, Neoplastic/genetics , Cells, Cultured , Cluster Analysis , Down-Regulation , Gene Expression Profiling , HEK293 Cells , Humans , Immunoblotting , Immunohistochemistry , Lung Neoplasms/genetics , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Mice , Mice, Inbred BALB C , Mice, Nude , Neoplasms/metabolism , Neoplasms/pathology , Pyrimidines/pharmacology , RNA Interference , Receptor, Fibroblast Growth Factor, Type 3/antagonists & inhibitors , Receptor, Fibroblast Growth Factor, Type 3/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction/drug effects , Signal Transduction/genetics , TOR Serine-Threonine Kinases/metabolism , src-Family Kinases/metabolismABSTRACT
In this study, we describe a novel self-contained, nonviral vector system for the rapid development of tetracycline (Tet)-inducible transgene expression systems in mammalian cell lines. To avoid multiple rounds of clonal selection for the establishment of stably transfected cell clones, as is necessary with conventional systems, we constructed a multicomplementary DNA(cDNA) expression vector that enables both one-step targeted genomic integration and conditional induction of transgene expression. This vector system consists of several modules including a Tet-inducible promoter directing the expression of a transgene and two Tet repressor expression units placed in tandem on a single vector. The cell clones, generated using a one-step phiC31 integrase-mediated chromosomal integration of the multi-cDNA expression construct, showed a stable and robust expression with high induction rates upon addition of doxycycline inducer in five different cell lines tested. By using this system, we show c-Src-induced cell transformation and anticancer cell therapy for this transformation in cultured fibroblast cells. The results show a rapid production and accumulation of target protein on addition of the inducer starting from extremely low background levels and reduction to background levels in a matter of days after the inducer was withdrawn from the culture medium.
Subject(s)
Gene Expression Regulation , Genetic Vectors , Tetracycline/pharmacology , Transgenes , Cell Line , Cell Line, Transformed , DNA, Complementary , Gene Transfer Techniques , HumansABSTRACT
The receptor tyrosine kinase Ror2 regulates cell migration by acting as a receptor or co-receptor for Wnt5a. Although Wnt5a has been implicated in the invasiveness of several types of tumors, the role of Ror2 in tumor invasion remains elusive. Here we show that osteosarcoma cell lines SaOS-2 and U2OS show invasive properties in vitro by activating Wnt5a/Ror2 signaling in a cell-autonomous manner. The suppressed expression of either Wnt5a or Ror2 in osteosarcoma cells inhibits cell invasiveness accompanying decreased invadopodia formation. Gene-expression profiling identified matrix metalloproteinase 13 (MMP-13) as one of the genes whose expression is downregulated in SaOS-2 cells following suppression of Ror2 expression. Reduced expression or activity of MMP-13 suppresses invasiveness of SaOS-2 cells. Moreover, expression of MMP-13 and cell invasiveness by Wnt5a/Ror2 signaling can be abrogated by an inhibitor of the Src-family protein tyrosine kinases (SFKs), suggesting the role of the SFKs in MMP-13 expression through Wnt5a/Ror2 signaling. We further show that activation of an SFK is inhibited by the suppressed expression of Ror2. Collectively, these results indicate that Wnt5a/Ror2 signaling involves the activation of a SFK, leading to MMP-13 expression, and that constitutively active Wnt5a/Ror2 signaling confers invasive properties on osteosarcoma cells in a cell-autonomous manner.
Subject(s)
Cell Movement/physiology , Proto-Oncogene Proteins/metabolism , Receptors, Cell Surface/metabolism , Signal Transduction/physiology , Wnt Proteins/metabolism , CSK Tyrosine-Protein Kinase , Cell Line, Tumor , Cell Movement/genetics , Enzyme Activation/drug effects , Extracellular Matrix/metabolism , Gene Expression Regulation, Neoplastic , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Humans , Immunoblotting , Matrix Metalloproteinase 13/genetics , Matrix Metalloproteinase 13/metabolism , Microscopy, Fluorescence , Neoplasm Invasiveness , Oligonucleotide Array Sequence Analysis , Osteosarcoma/genetics , Osteosarcoma/metabolism , Osteosarcoma/pathology , Protein-Tyrosine Kinases/antagonists & inhibitors , Protein-Tyrosine Kinases/metabolism , Proto-Oncogene Proteins/genetics , Pyrimidines/pharmacology , RNA, Small Interfering/genetics , Receptor Tyrosine Kinase-like Orphan Receptors , Receptors, Cell Surface/genetics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction/genetics , Transfection , Wnt Proteins/genetics , Wnt-5a Protein , src-Family KinasesABSTRACT
Src tyrosine kinase plays key roles in signal transduction following growth factor stimulation and integrin-mediated cell-substrate adhesion. Since src-signal transduction defects are implicated in a multitude of human diseases, we have sought to develop new ways to identify small molecule inhibitors using a yeast-based, activated-src over-expression system. In the present study, we describe the identification of a unique src-signal transduction inhibitor, UCS15A. UCS15A was found to inhibit the src specific tyrosine phosphorylation of numerous proteins in v-src-transformed cells. Two of these phosphoproteins were identified as bona-fide src substrates, cortactin and Sam68. UCS15A differed from conventional src-inhibitors in that it did not inhibit the tyrosine kinase activity of src. In addition, UCS15A appeared to differ from src-destabilizing agents such as herbimycin and radicicol that destabilize src by interfering with Hsp90. Our studies suggest that UCS15A exerted its src-inhibitory effects by a novel mechanism that involved disruption of protein-protein interactions mediated by src. One of the biological consequences of src-inhibition by UCS15A was its ability to inhibit the bone resorption activity of osteoclasts in vitro. These data suggest that UCS15A may inhibit the bone resorption activity of osteoclasts, not by inhibiting src tyrosine kinase activity, but by disrupting the interaction of proteins associated with src, thereby modulating downstream events in the src signal transduction pathway.
Subject(s)
Anti-Bacterial Agents/pharmacology , Benzaldehydes/pharmacology , Bone Resorption/drug therapy , Osteoclasts/drug effects , Signal Transduction/drug effects , src-Family Kinases/physiology , 3T3 Cells/drug effects , 3T3 Cells/metabolism , Adaptor Proteins, Signal Transducing , Animals , Benzoquinones , Cell Transformation, Neoplastic , Cortactin , DNA-Binding Proteins , Enzyme Activation , Enzyme Inhibitors/pharmacology , Genes, src/physiology , Humans , Lactams, Macrocyclic , Lactones/pharmacology , Macrolides , Male , Mice , Microfilament Proteins/metabolism , Organ Culture Techniques , Phosphorylation/drug effects , Quinones/pharmacology , RNA-Binding Proteins/metabolism , Rats , Rifabutin/analogs & derivatives , Tyrosine/metabolism , src-Family Kinases/antagonists & inhibitorsABSTRACT
The genes encoding three RNases were cloned from the style of a self-incompatible cultivar, Nijisseiki (S2S4), and its self-compatible mutant, Osa-Nijisseiki (S2S4sm, sm means stylar part mutant), of Japanese pear. For Nijisseiki, cDNAs coding for two S-RNase (S2-RNase and S4-RNase) and an RNase unrelated to self-incompatibility (non-S-RNase) were cloned from the stylar cDNA library. The cDNAs coding for S2-RNase, S4-RNase, and non-S-RNase include 678-, 684-, and 681-bp open reading frames, respectively. Their deduced amino acid sequences were composed of signal peptides and mature RNases (201-203 residues) which were verified by partial amino acid sequencing. The primary structures of mature proteins revealed that these RNases are of the RNase T2 type; only the two S-RNases have several potential N-glycosylation sites and 60% of their amino acid residues are identical, compared with 25% sequence identity with the non-S-RNase. Such a distinct difference in the primary structures between S-RNases and non-S-RNase has not previously been reported and may be a feature typical of S-RNases in the family Rosaceae. Similar experiments were performed for Osa-Nijisseiki. The cDNAs coding for S2-RNase and non-S-RNase were similarly cloned from the stylar cDNA library. However, the cDNA coding for S4-RNase was neither amplified by PCR nor cloned from the library, suggesting that the mutation of self-incompatible Nijisseiki to self-compatible Osa-Nijisseiki is due to a failure of expression of S4-RNase. These results lead to the idea that Osa-Nijiisseiki is a variant of Nijisseiki in which the S4-allelic gene in the S-locus is exclusively mutated or deleted, causing severely impaired or suppressed expression of its gene product, S4-RNase, at the style.